Is Voyager Therapeutics Stock a Good Investment?
Voyager Therapeutics Investment Advice | VYGR |
- Examine Voyager Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Voyager Therapeutics' leadership team and their track record. Good management can help Voyager Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Voyager Therapeutics' business and its evolving consumer preferences.
- Compare Voyager Therapeutics' performance and market position to its competitors. Analyze how Voyager Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Voyager Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Voyager Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Voyager Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Voyager Therapeutics is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Voyager Therapeutics Stock
Researching Voyager Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 64.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.72. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Voyager Therapeutics recorded a loss per share of 1.13. The entity had not issued any dividends in recent years.
To determine if Voyager Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Voyager Therapeutics' research are outlined below:
| Voyager Therapeutics generated a negative expected return over the last 90 days | |
| Voyager Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 80 M. Net Loss for the year was (65 M) with loss before overhead, payroll, taxes, and interest of (47.37 M). | |
| Voyager Therapeutics currently holds about 148.06 M in cash with (15.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.83. | |
| Roughly 64.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Acquisition by Pfreundschuh Peter P. of 60000 shares of Voyager Therapeutics at 7.6 subject to Rule 16b-3 |
Voyager Therapeutics Quarterly Cost Of Revenue |
|
Voyager Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Voyager Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Voyager Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Voyager Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Voyager Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-03 | 2023-06-30 | -0.57 | -0.51 | 0.06 | 10 | ||
2023-03-07 | 2022-12-31 | -0.55 | -0.61 | -0.06 | 10 | ||
2016-11-10 | 2016-09-30 | -0.41 | -0.35 | 0.06 | 14 | ||
2021-05-10 | 2021-03-31 | -0.66 | -0.58 | 0.08 | 12 | ||
2021-08-09 | 2021-06-30 | -0.71 | -0.8 | -0.09 | 12 | ||
2016-05-12 | 2016-03-31 | -0.38 | -0.29 | 0.09 | 23 | ||
2017-03-15 | 2016-12-31 | -0.46 | -0.57 | -0.11 | 23 | ||
2017-08-08 | 2017-06-30 | -0.61 | -0.73 | -0.12 | 19 |
Voyager Therapeutics Target Price Consensus
Voyager target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Voyager Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 11 | Strong Buy |
Most Voyager analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Voyager stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Voyager Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationVoyager Therapeutics Target Price Projection
Voyager Therapeutics' current and average target prices are 3.91 and 17.10, respectively. The current price of Voyager Therapeutics is the price at which Voyager Therapeutics is currently trading. On the other hand, Voyager Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Voyager Therapeutics Market Quote on 25th of March 2025
Target Price
Analyst Consensus On Voyager Therapeutics Target Price
Voyager Therapeutics Analyst Ratings
Voyager Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Voyager Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Voyager Therapeutics' financials, market performance, and future outlook by experienced professionals. Voyager Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Voyager Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Voyager Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Voyager Therapeutics backward and forwards among themselves. Voyager Therapeutics' institutional investor refers to the entity that pools money to purchase Voyager Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Great Point Partners Llc | 2024-12-31 | 826.8 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 447.1 K | Northern Trust Corp | 2024-12-31 | 418.7 K | Prudential Financial Inc | 2024-12-31 | 330.3 K | Globeflex Capital, L.p. | 2024-12-31 | 291.3 K | Goldman Sachs Group Inc | 2024-12-31 | 291.3 K | Wellington Management Company Llp | 2024-12-31 | 261.3 K | Fiduciary Trust Co | 2024-12-31 | 259.4 K | Jpmorgan Chase & Co | 2024-12-31 | 241.6 K | Armistice Capital, Llc | 2024-12-31 | 5.4 M | Blackrock Inc | 2024-12-31 | 5.4 M |
Voyager Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 215.86 M.Market Cap |
|
Voyager Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.17) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.17) | (0.17) | |
| Return On Equity | (0.22) | (0.23) |
Determining Voyager Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Voyager Therapeutics is a good buy. For example, gross profit margin measures Voyager Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Voyager Therapeutics' profitability and make more informed investment decisions.
Evaluate Voyager Therapeutics' management efficiency
Voyager Therapeutics has return on total asset (ROA) of (0.1399) % which means that it has lost $0.1399 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2425) %, meaning that it created substantial loss on money invested by shareholders. Voyager Therapeutics' management efficiency ratios could be used to measure how well Voyager Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/25/2025, Return On Tangible Assets is likely to drop to -0.17. In addition to that, Return On Capital Employed is likely to drop to -0.25. At this time, Voyager Therapeutics' Non Current Assets Total are relatively stable compared to the past year. As of 03/25/2025, Non Currrent Assets Other is likely to grow to about 72 M, while Other Assets are likely to drop 1.09.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.20 | 6.02 | |
| Tangible Book Value Per Share | 5.20 | 6.02 | |
| Enterprise Value Over EBITDA | (3.59) | (3.77) | |
| Price Book Value Ratio | 1.09 | 1.04 | |
| Enterprise Value Multiple | (3.59) | (3.77) | |
| Price Fair Value | 1.09 | 1.04 | |
| Enterprise Value | 299.3 M | 202 M |
At Voyager Therapeutics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 0.991 |
Basic technical analysis of Voyager Stock
As of the 25th of March, Voyager Therapeutics has the Coefficient Of Variation of (542.60), variance of 13.96, and Risk Adjusted Performance of (0.16). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Voyager Therapeutics, as well as the relationship between them. Please validate Voyager Therapeutics market risk adjusted performance and treynor ratio to decide if Voyager Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 3.91 per share. Given that Voyager Therapeutics has information ratio of (0.18), we advise you to double-check Voyager Therapeutics's current market performance to make sure the company can sustain itself at a future point.Voyager Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Voyager Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Voyager Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Voyager Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Voyager Therapeutics' Outstanding Corporate Bonds
Voyager Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Voyager Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Voyager bonds can be classified according to their maturity, which is the date when Voyager Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| VMC 715 30 NOV 37 Corp BondUS929160AG40 | View | |
| VULCAN MATLS 45 Corp BondUS929160AV17 | View | |
| VULCAN MATLS 39 Corp BondUS929160AT60 | View | |
| VULCAN MATLS 45 Corp BondUS929160AS87 | View |
Understand Voyager Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Voyager Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.16) | |||
| Market Risk Adjusted Performance | (0.72) | |||
| Mean Deviation | 2.54 | |||
| Coefficient Of Variation | (542.60) | |||
| Standard Deviation | 3.74 | |||
| Variance | 13.96 | |||
| Information Ratio | (0.18) | |||
| Jensen Alpha | (0.66) | |||
| Total Risk Alpha | (0.55) | |||
| Treynor Ratio | (0.73) | |||
| Maximum Drawdown | 26.16 | |||
| Value At Risk | (4.89) | |||
| Potential Upside | 4.8 | |||
| Skewness | (2.36) | |||
| Kurtosis | 12.08 |
| Risk Adjusted Performance | (0.16) | |||
| Market Risk Adjusted Performance | (0.72) | |||
| Mean Deviation | 2.54 | |||
| Coefficient Of Variation | (542.60) | |||
| Standard Deviation | 3.74 | |||
| Variance | 13.96 | |||
| Information Ratio | (0.18) | |||
| Jensen Alpha | (0.66) | |||
| Total Risk Alpha | (0.55) | |||
| Treynor Ratio | (0.73) | |||
| Maximum Drawdown | 26.16 | |||
| Value At Risk | (4.89) | |||
| Potential Upside | 4.8 | |||
| Skewness | (2.36) | |||
| Kurtosis | 12.08 |
Consider Voyager Therapeutics' intraday indicators
Voyager Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Voyager Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Voyager Therapeutics Corporate Filings
8K | 11th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 24th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Voyager Stock media impact
Far too much social signal, news, headlines, and media speculation about Voyager Therapeutics that are available to investors today. That information is available publicly through Voyager media outlets and privately through word of mouth or via Voyager internal channels. However, regardless of the origin, that massive amount of Voyager data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Voyager Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Voyager Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Voyager Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Voyager Therapeutics alpha.
Voyager Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Voyager Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Voyager Therapeutics Historical Investor Sentiment
Investor biases related to Voyager Therapeutics' public news can be used to forecast risks associated with an investment in Voyager. The trend in average sentiment can be used to explain how an investor holding Voyager can time the market purely based on public headlines and social activities around Voyager Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Voyager Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Voyager Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Voyager Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Voyager Therapeutics.
Voyager Therapeutics Corporate Management
| Sandrock MD | CEO Pres | Profile | |
| Dr MBA | Chief Officer | Profile | |
| JD Esq | Chief Officer | Profile | |
| Todd Carter | Chief Officer | Profile |
Additional Tools for Voyager Stock Analysis
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.